Asbestos Lung Cancer Treatment: What Patients and Families Need to Know
A diagnosis of lung cancer linked to asbestos exposure raises immediate, urgent questions — and the most pressing is almost always: what can actually be done? Asbestos lung cancer treatment has advanced considerably over the past decade, and while there is no entirely separate treatment pathway exclusive to asbestos-related cases, oncologists do tailor their approach based on how exposure has shaped the disease.
The options available today are more targeted, more personalised, and more effective than they were even a few years ago. This post sets out the current treatment landscape clearly — covering surgery, chemotherapy, radiotherapy, targeted therapies, immunotherapy, and emerging clinical trials — alongside the practical steps you can take to protect yourself and others from future exposure.
Understanding Asbestos-Related Lung Cancer
Two Distinct Diseases — Not One
Asbestos exposure is associated with two separate cancers affecting the chest, and conflating them leads to real confusion about treatment. The first is mesothelioma — a cancer of the pleura (the lining of the lungs), almost exclusively caused by asbestos. The second is lung cancer (carcinoma) — cancer that develops within the lung tissue itself, which asbestos can cause or significantly contribute to.
This post focuses on lung carcinoma. Mesothelioma is a different disease with its own distinct treatment protocols and is not covered here.
Types of Asbestos-Related Lung Cancer
Asbestos-related lung cancer falls into the same two broad categories as other lung cancers:
- Non-small cell lung cancer (NSCLC) — the most common type, accounting for the large majority of cases. Includes adenocarcinoma, squamous cell carcinoma, and large cell carcinoma.
- Small cell lung cancer (SCLC) — less common but more aggressive, with a tendency to spread rapidly and early.
Which type a patient has significantly shapes the treatment decisions made by their oncology team. Accurate pathological diagnosis is the essential first step.
How Asbestos Fibres Cause Cancer
When asbestos fibres are inhaled, they lodge deep in the lung tissue. The body cannot expel them. Over time, they trigger chronic inflammation, cellular damage, and scarring — and this repeated injury to cell DNA creates the conditions for malignant change.
The latency period is long — typically anywhere from 15 to 40 years after initial exposure. Many people are diagnosed in later life, sometimes long after leaving high-risk occupations such as construction, shipbuilding, insulation installation, or pipe lagging.
Smoking dramatically compounds the risk. Someone who both smoked and was heavily exposed to asbestos faces a substantially elevated lung cancer risk compared to either factor alone. Smoking cessation is therefore a medical priority for anyone with a known asbestos exposure history.
Current Asbestos Lung Cancer Treatment Options
Oncologists treating asbestos-related lung cancer use the same core treatment modalities as for other lung cancers. What differs is how those options are selected and sequenced — shaped by the cancer type, stage, the patient’s overall health, and their exposure and smoking history.
Surgery
Surgery is most relevant for non-small cell lung cancer caught at an early stage, before it has spread beyond the lung. The main surgical procedures include:
- Lobectomy — removal of the affected lobe of the lung. This is the most commonly performed procedure for operable NSCLC.
- Pneumonectomy — removal of an entire lung, reserved for more extensive disease where a lobectomy wouldn’t achieve clear margins.
- Wedge resection or segmentectomy — removal of a smaller portion of the lung, considered when a patient’s lung function is too limited to tolerate a full lobectomy.
For small cell lung cancer, surgery is rarely appropriate. SCLC spreads quickly and is usually beyond surgical reach by the time it’s diagnosed. In the very rare cases where it’s detected at an extremely early, localised stage, surgery may be considered — but it would typically be combined with chemotherapy.
Chemotherapy
Chemotherapy is central to treating both types of asbestos-related lung cancer and is used in several different contexts:
- Before surgery (neoadjuvant) — to shrink tumours and improve the chances of successful resection.
- After surgery (adjuvant) — to reduce the risk of recurrence by targeting remaining cancer cells.
- As the primary treatment — particularly for SCLC or later-stage NSCLC where surgery isn’t viable.
- Alongside radiotherapy (chemoradiation) — for locally advanced disease.
For NSCLC, platinum-based combinations — such as cisplatin or carboplatin paired with paclitaxel or pemetrexed — are commonly used. For SCLC, etoposide combined with a platinum agent is the standard first-line approach.
The choice of regimen depends on the cancer’s stage, the patient’s kidney and liver function, and whether targeted therapy is also being considered.
Radiotherapy
Radiotherapy uses high-energy radiation to destroy cancer cells or slow their growth. It plays several roles in asbestos lung cancer treatment:
- Radical radiotherapy — used with curative intent in patients with localised NSCLC who aren’t suitable for surgery.
- Stereotactic ablative radiotherapy (SABR) — a highly precise form increasingly used for early-stage NSCLC, particularly in older or frailer patients.
- Palliative radiotherapy — used to manage symptoms such as pain, breathlessness, or haemoptysis in advanced disease.
- Prophylactic cranial irradiation (PCI) — used in SCLC to reduce the risk of the cancer spreading to the brain.
Targeted Therapies and Immunotherapy
Targeted Therapies
One of the most significant developments in lung cancer treatment over the past decade has been the rise of targeted therapies — drugs designed to attack specific genetic mutations or proteins that drive cancer growth. These aren’t exclusive to asbestos-related cases, but they are directly relevant to patients whose tumours carry certain genetic markers.
Oncologists routinely test NSCLC biopsies for mutations including:
- EGFR mutations — treated with drugs such as osimertinib (Tagrisso).
- ALK rearrangements — treated with drugs such as alectinib or crizotinib.
- KRAS G12C mutations — now targetable with sotorasib (Lumakras).
- ROS1, RET, MET, and BRAF alterations — each with specific inhibitor options available or in development.
If a patient’s tumour carries one of these mutations, targeted therapy can be highly effective — often with a better tolerability profile than traditional chemotherapy. Molecular testing of the tumour is now standard practice in NHS lung cancer care.
Immunotherapy
Immunotherapy has transformed lung cancer treatment and is particularly relevant for patients with asbestos-related lung cancer who don’t have a targetable mutation. These drugs — known as immune checkpoint inhibitors — work by blocking proteins that cancer cells use to hide from the immune system. By removing that brake, the body’s own defences can recognise and attack the cancer more effectively.
The most widely used immunotherapy agents in lung cancer include:
- Pembrolizumab (Keytruda) — approved for use in NSCLC, either alone or combined with chemotherapy, depending on PD-L1 expression levels.
- Nivolumab (Opdivo) — used in previously treated advanced NSCLC.
- Atezolizumab and durvalumab — available in specific settings including SCLC and locally advanced NSCLC.
Immunotherapy is often combined with chemotherapy in the first-line setting. Patients whose tumours express high levels of the PD-L1 protein may respond particularly well. Oncologists use biomarker testing to determine which patients are most likely to benefit.
Clinical trials continue to explore new immunotherapy combinations, including approaches specifically designed to address the inflammatory tumour microenvironment that chronic asbestos exposure tends to create.
Clinical Trials and Emerging Treatments
For patients with asbestos-related lung cancer — particularly those with advanced disease or cancers that haven’t responded to standard treatments — clinical trials offer access to therapies not yet widely available. This is an active and rapidly evolving area of oncology.
Current areas of active research include:
- Antibody-drug conjugates (ADCs) — targeted agents that deliver chemotherapy directly to cancer cells, minimising wider damage.
- Novel immunotherapy combinations — including dual checkpoint blockade and combinations with anti-angiogenic agents.
- CAR-T cell therapy — still early-stage for lung cancer but showing promise in trials.
- Vaccines and adoptive cell therapies — designed to train the immune system to target specific tumour antigens.
Your oncologist or a specialist lung cancer centre can advise on relevant trials. The NIHR Clinical Research Network maintains an up-to-date register of trials currently recruiting in the UK.
What Affects Prognosis?
Prognosis for asbestos-related lung cancer depends on several factors, and understanding them helps patients and families make informed decisions about treatment and support.
- Stage at diagnosis — earlier detection consistently leads to better outcomes. Stage I and II NSCLC, caught before the cancer has spread, has substantially higher survival rates than stage IV disease.
- Cancer type — NSCLC and SCLC behave very differently, and prognosis varies accordingly.
- Molecular profile — patients with targetable mutations who respond to targeted therapy often achieve longer survival than historical averages would suggest.
- Overall health and lung function — patients with asbestosis or other respiratory comorbidities may have more limited treatment options.
- Smoking history — continuing to smoke worsens prognosis and can reduce the effectiveness of some treatments.
The outlook for asbestos lung cancer treatment has improved considerably as the range of options has expanded. Early detection through surveillance programmes for those with known significant exposure — where available — remains one of the most meaningful ways to improve outcomes.
Why Your Exposure History Matters to Your Medical Team
If you’re being assessed for lung cancer, make sure your medical team knows your full occupational and exposure history. This isn’t just background information — it has direct clinical relevance.
Your exposure history can:
- Influence decisions about which molecular tests to run on tumour biopsies.
- Open access to industrial injury compensation or support through the Pneumoconiosis etc. (Workers’ Compensation) Act or IIDB (Industrial Injuries Disablement Benefit).
- Help clinicians assess your overall lung health, including any coexisting asbestosis or pleural disease.
- Qualify you for referral to specialist centres with particular experience in asbestos-related cancers.
If you’ve worked in a high-risk occupation — construction, shipbuilding, insulation, pipe lagging, roofing, or demolition — document this history as precisely as you can, including job roles, employers, and approximate dates. The more detail your clinical team has, the better placed they are to support you.
Protecting Others from Future Asbestos Exposure
For those who work in or around older buildings, the risk of ongoing asbestos exposure remains real. Asbestos is still present in a large number of commercial and domestic properties built before 2000 — in floor tiles, pipe lagging, ceiling tiles, textured coatings, and roofing materials.
Under the Control of Asbestos Regulations, duty holders — including employers, building owners, and managing agents — are legally required to manage asbestos-containing materials in non-domestic premises. This means knowing where asbestos is, assessing its condition, and ensuring it doesn’t present a risk to workers or occupants.
If you manage a property and don’t yet have an asbestos management survey in place, arranging one is the single most important step you can take to protect everyone who uses that building. It’s not just a legal obligation — it’s a direct means of preventing the kind of exposure that leads to the diagnoses described in this post.
What a Management Survey Involves
An asbestos management survey is a thorough inspection of a property to locate, as far as reasonably practicable, all asbestos-containing materials (ACMs) that could be disturbed during normal occupancy and maintenance. The surveyor will assess the condition of any ACMs found, assign a risk rating, and produce a register that forms the basis of your asbestos management plan.
This is the foundational document that protects your workers, your tenants, and your contractors. Without it, you have no reliable way of knowing what risks exist within your building — and no defensible position if something goes wrong.
Where Is Asbestos Most Commonly Found?
In buildings constructed or refurbished before 2000, asbestos may be present in:
- Ceiling tiles and textured coatings (such as Artex)
- Floor tiles and their adhesive backing
- Pipe and boiler lagging
- Roof sheets, soffits, and guttering
- Partition walls and fire doors
- Electrical equipment and switchgear panels
Many of these materials are in good condition and present minimal risk when left undisturbed. The danger arises when they’re drilled, cut, sanded, or otherwise disturbed — releasing fibres into the air where they can be inhaled.
The Link Between Poor Asbestos Management and Future Disease
Every case of asbestos-related lung cancer being treated today reflects an exposure that happened years or decades ago — often in a workplace where asbestos was poorly managed or not managed at all. The treatment advances described in this post are real and meaningful. But they come after the damage is done.
Prevention is categorically more effective than treatment. The duty holder obligations under the Control of Asbestos Regulations exist precisely to break the chain between exposure and disease. Fulfilling those obligations properly — with a professional survey, a maintained register, and a clear management plan — is the most direct contribution a property manager or employer can make to reducing future cases.
If you’re based in London and need to arrange a survey, Supernova’s team covers the full capital — you can find out more about our asbestos survey London service on our website. We also provide full coverage across the North West — our asbestos survey Manchester team works with commercial and residential clients throughout Greater Manchester. And for the Midlands, our asbestos survey Birmingham service covers the city and surrounding areas.
Frequently Asked Questions
Is asbestos lung cancer treated differently from other lung cancers?
Not through a separate treatment pathway, but oncologists do take asbestos exposure into account when making treatment decisions. It can influence which molecular tests are ordered, how the patient’s overall lung health is assessed, and whether there are coexisting conditions such as asbestosis or pleural disease that affect treatment options. The core modalities — surgery, chemotherapy, radiotherapy, targeted therapy, and immunotherapy — are the same as for other lung cancers.
How long after asbestos exposure does lung cancer develop?
The latency period is typically between 15 and 40 years. This means many people are diagnosed long after they’ve left the occupation where exposure occurred. If you have a history of working in construction, shipbuilding, insulation, or other high-risk industries, it’s worth discussing this with your GP — particularly if you have any respiratory symptoms.
Does smoking make asbestos-related lung cancer worse?
Yes, significantly. The combination of asbestos exposure and smoking creates a substantially higher lung cancer risk than either factor alone. Smoking cessation is a clinical priority for anyone with a known asbestos exposure history, and continuing to smoke can reduce the effectiveness of some cancer treatments and worsen overall prognosis.
What is the difference between mesothelioma and asbestos lung cancer?
Mesothelioma is a cancer of the pleura — the lining around the lungs — and is almost exclusively caused by asbestos exposure. Asbestos lung cancer (carcinoma) develops within the lung tissue itself. They are distinct diseases with different pathology, different treatment protocols, and different prognoses. A definitive diagnosis requires pathological testing, and the treatment approach differs significantly between the two.
What should I do if I think I was exposed to asbestos at work?
Tell your GP and ensure your full occupational history is documented in your medical records. If you’re already being investigated or treated for lung cancer, make sure your oncology team has this information — it can affect clinical decisions and may also open access to industrial injury benefits or compensation. Document your work history as precisely as possible, including job roles, employers, and the approximate period of exposure.
Speak to Supernova About Your Asbestos Survey
If you’re responsible for a building and need professional asbestos surveying, Supernova Asbestos Surveys has completed over 50,000 surveys nationwide. Our surveyors are experienced, accredited, and work to the standards set out in HSG264 and the Control of Asbestos Regulations.
Call us on 020 4586 0680 or visit asbestos-surveys.org.uk to arrange a survey or discuss your requirements. Whether you need a management survey, a refurbishment and demolition survey, or sampling and testing, we can help.